Phase 3 Recruiting NIH
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in Wisconsin: - Aurora Cancer Care-Southern Lakes VLCC — Burlington, Wisconsin
- Aurora Saint Luke's South Shore — Cudahy, Wisconsin
- Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
- Aurora Health Care Germantown Health Center — Germantown, Wisconsin
- Aurora Cancer Care-Grafton — Grafton, Wisconsin
Phase 2, Phase 3 Recruiting Academic/Other
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…
Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in Wisconsin: - Froedtert Menomonee Falls Hospital — Menomonee Falls, Wisconsin
- Medical College of Wisconsin — Milwaukee, Wisconsin
- Froedtert and MCW Moorland Reserve Health Center — New Berlin, Wisconsin
- Drexel Town Square Health Center — Oak Creek, Wisconsin
- Froedtert West Bend Hospital/Kraemer Cancer Center — West Bend, Wisconsin
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in Wisconsin: - Research Site — Milwaukee, Wisconsin
Phase 3 Recruiting Academic/Other
This phase III trial compares cetuxumab to chemotherapy, carboplatin and paclitaxel, with intensity modulated radiation therapy for the treatment of patients with head and neck cancer who are unable to receive cisplatin. Cetuximab is in a …
Sponsor: NRG Oncology
NCT ID: NCT07441681
Sites in Wisconsin: - Aspirus Cancer Care-Antigo-Volm Cancer Center — Antigo, Wisconsin
- Froedtert Menomonee Falls Hospital — Menomonee Falls, Wisconsin
- Medical College of Wisconsin — Milwaukee, Wisconsin
- Froedtert and MCW Moorland Reserve Health Center — New Berlin, Wisconsin
- Drexel Town Square Health Center — Oak Creek, Wisconsin
Phase 2, Phase 3 Recruiting Industry
Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizum…
Sponsor: Bicara Therapeutics
NCT ID: NCT06788990
Sites in Wisconsin: - Site #0141 — Madison, Wisconsin
- Site #0157 — Madison, Wisconsin
- Site # 0153 — Milwaukee, Wisconsin
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …
Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Sites in Wisconsin: - Medical College of Wisconsin - Froedtert Hospital Cancer Center — Milwaukee, Wisconsin
Phase 2 Recruiting Network
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in Wisconsin: - ThedaCare Regional Cancer Center — Appleton, Wisconsin
- Duluth Clinic Ashland — Ashland, Wisconsin
- Northwest Wisconsin Cancer Center — Ashland, Wisconsin
- Aurora Cancer Care-Southern Lakes VLCC — Burlington, Wisconsin
- Aurora Saint Luke's South Shore — Cudahy, Wisconsin
Phase 2 Recruiting NIH
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Wisconsin: - Duluth Clinic Ashland — Ashland, Wisconsin
- Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
- Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
- Saint Vincent Hospital Cancer Center at Saint Mary's — Green Bay, Wisconsin
- Gundersen Lutheran Medical Center — La Crosse, Wisconsin
Phase 2 Recruiting NIH
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04671667
Sites in Wisconsin: - Aspirus Cancer Care-Antigo-Volm Cancer Center — Antigo, Wisconsin
- ThedaCare Regional Cancer Center — Appleton, Wisconsin
- HSHS Sacred Heart Hospital — Eau Claire, Wisconsin
- Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
- Saint Vincent Hospital Cancer Center at Saint Mary's — Green Bay, Wisconsin
Phase 1, Phase 2 Recruiting Industry
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with adv…
Sponsor: Turning Point Therapeutics, Inc.
NCT ID: NCT03093116
Sites in Wisconsin: - Local Institution - 2145 — Appleton, Wisconsin
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combinatio…
Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT04198766
Sites in Wisconsin: - Froedtert Hospital and the Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…
Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in Wisconsin: - Froedtert & MCW Cancer Center — Milwaukee, Wisconsin
Phase 1, Phase 2 Recruiting Industry
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants with adva…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Wisconsin: - University of Wisconsin- Madison — Madison, Wisconsin
Phase 1, Phase 2 Recruiting Industry
Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Wisconsin: - University of Wisconsin — Madison, Wisconsin
Phase 2 Recruiting Industry
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it…
Sponsor: Bayer
NCT ID: NCT06760819
Sites in Wisconsin: - UW Health Carbone Cancer Center — Madison, Wisconsin
Phase 2 Recruiting Academic/Other
The goal of this clinical trial is to compare a new way of using magnetic resonance-guided adaptive radiation therapy (MRgART) to the standard of care linear accelerator (LINAC) radiation treatment in people with cancer in the thoracic reg…
Sponsor: University of Wisconsin, Madison
NCT ID: NCT07132918
Sites in Wisconsin: - University of Wisconsin - Madison — Madison, Wisconsin
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Wisconsin: - Exelixis Clinical Site #33 — Milwaukee, Wisconsin
Phase 1 Recruiting Industry
Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant malignancies
Sponsor: AstraZeneca
NCT ID: NCT05877599
Sites in Wisconsin: - Research Site — Milwaukee, Wisconsin
Recruiting Industry
The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.
Sponsor: Tempus AI
NCT ID: NCT06163534
Sites in Wisconsin: - ThedaCare — Appleton, Wisconsin
NA Recruiting Academic/Other
This study will evaluate if the sponge capsule device can accurately detect the presence of Barrett's Esophagus and prevalent dysplasia/adenocarcinoma detection, in a screening population, with and without chronic gastroesophageal reflux d…
Sponsor: Mayo Clinic
NCT ID: NCT03961945
Sites in Wisconsin: - Mayo Clinic Health System-Eau Claire — Eau Claire, Wisconsin
- Mayo Clinic Health System-Franciscan Healthcare — La Crosse, Wisconsin
NA Recruiting Academic/Other
The goal of this clinical trial is to determine whether accelerated radiotherapy (involving 6 treatments per week) is better than standard radiotherapy (involving 5 treatments per week) at treating cancer of the head and neck when initiate…
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06607406
Sites in Wisconsin: - Advocate Aurora Radiation Oncology — Milwaukee, Wisconsin
NA Recruiting Academic/Other
This study is a randomized trial examining the impact of expiratory muscle strength training (EMST) on maintenance of safe and efficient oropharyngeal swallow function in persons with cancer of the head and neck (HNCA) undergoing treatment…
Sponsor: University of Wisconsin, Milwaukee
NCT ID: NCT03916809
Sites in Wisconsin: - University of Wisconsin Milwaukee — Milwaukee, Wisconsin
- Froedtert Hospital — Milwaukee, Wisconsin